1 / 10

Limitations in drug discovery

Limitations in drug discovery. More than 90% compounds entering clinical trials fail to demonstrate safety and efficacy in human, despite evidence of safety and effectiveness in pre-clinical models

elijah
Télécharger la présentation

Limitations in drug discovery

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Limitations in drug discovery • More than 90% compounds entering clinical trials fail to demonstrate safety and efficacy in human, despite evidence of safety and effectiveness in pre-clinical models • High failure rates indicate the limited ability of pre-clinical models to predict patient benefit in human populations.

  2. Potential of Human genetics to overcome limitations in drug discovery • Human genetics as “Experiment of nature” to prioritize molecular targets in drug discovery • => naturally occurring conditions (mutations) • that modulate (gain- or loss-of–function) a biological target (gene) • with reproducible effect (decreased or increased risk) • on human physiology (trait = appropriate proxy for drug efficacy) • -> mimic the effect of therapeutic modulation of a target • -> serve as estimate of dose-response curves (function-phenotype curves)

  3. PCSK9, LDL levels and coronary heart disease 1 1. PCSK9GOFalleles: increased LDL levels 2003

  4. PCSK9, LDL levels and coronary heart disease 1 1. PCSK9GOFalleles: increased LDL levels 2003 2. PCSK9LOFalleles: decreased LDL levels 2005-2006 2

  5. PCSK9, LDL levels and coronary heart disease 1 1. PCSK9GOFalleles: increased LDL levels 2003 2. PCSK9LOFalleles: decreased LDL levels 2005-2006 2

  6. PCSK9, LDL levels and coronary heart disease 1 1. PCSK9GOFalleles: increased LDL levels 2003 2. PCSK9LOFalleles: decreased LDL levels 2005-2006 2

  7. PCSK9, LDL levels and coronary heart disease 1 1. PCSK9GOFalleles: increased LDL levels 2003 2. PCSK9LOFalleles: decreased LDL levels 2005-2006 3. PCSK9LOFalleles: protect against CHD 2006 4. 2 3

  8. PCSK9, LDL levels and coronary heart disease 1 1. PCSK9GOFalleles: increased LDL levels 2003 2. PCSK9LOFalleles: decreased LDL levels 2005-2006 3. PCSK9LOFalleles: protect against CHD 2006 4. PCSK9LOFalleles: no obvious adverse events 2006 2 3 4

  9. PCSK9, LDL levels and coronary heart disease 1 1. PCSK9GOFalleles: increased LDL levels 2003 2. PCSK9LOFalleles: decreased LDL levels 2005-2006 3. PCSK9LOFalleles: protect against CHD 2006 4. PCSK9LOFalleles: no obvious adverse events 2006 high PCSK9 GOF alleles 2 3 Risk of CHD 4 PCSK9 LOF alleles low low high LDL levels

  10. PCSK9, LDL levels and coronary heart disease 1 1. PCSK9GOFalleles: increased LDL levels 2003 2. PCSK9LOFalleles: decreased LDL levels 2005-2006 3. PCSK9LOFalleles: protect against CHD 2006 4. PCSK9LOFalleles: no obvious adverse events 2006 5. Clinical trials: monoclonal antibody to PCSK9 2012 high PCSK9 GOF alleles 2 3 Risk of CHD 4 PCSK9 LOF alleles 5 low low high LDL levels

More Related